Ipsos’ Syndicated ‘Lab Mapping’ Study Launches in Australia

16th November, 2017

Ipsos Healthcare, the global healthcare business of leading market research company Ipsos, has launched its syndicated ‘Lab Mapping’ Study in Australia. The study, already available in US and Europe, delivers a comprehensive picture of the laboratories involved in cancer biomarker testing.

Biomarker testing is becoming increasing important in the diagnosis and treatment across a range of cancer tumours – enabling patients to receive more targeted therapies resulting in better outcomes, particularly in terms of overall survival.

As a key component of Ipsos’ Oncology Molecular Diagnostics Portfolio, the Lab Mapping Study collects a wide range of information from Lab Directors across Australia. The resulting data enables subscribers to: identify the type, structure and workforce of the laboratories; gather details around testing volume and tissue flow; and quantify the volume of testing carried out by cancer type and methodology of biomarker testing.

Pieter De Richter, Head of Ipsos Healthcare’s Real World Evidence Portfolio in Asia Pacific, Middle East & North Africa, said: “The Molecular Diagnostics landscape in Oncology is evolving rapidly. The Lab Mapping Study allows pharmaceutical companies and molecular diagnostics manufacturers to better understand the workflow between the various types of labs involved with biomarker testing in each country, and how they are adapting to the changes in the marketplace. Combined with the Molecular Diagnostics Monitor, which focuses on Oncologist and Pathologist perceptions and behaviour, the Lab Mapping Study provides a holistic, multi-stakeholder view of cancer biomarker testing.”

- Ends –

For further information contact:
 

• Pieter De Richter, Head of Syndicated Real World Evidence, APAC & MENA

Tel: +601 2290 0315; Email: [email protected]

• Victoria Allan, Head of Syndicated Real World Evidence, Australia

Tel: +61 2 9900 5192; Email: [email protected]

• Joanna Butcher, Syndicated Marketing Communications Director
  Tel: +44 (0)7818 422117; Email: [email protected]    

About Ipsos Healthcare

Ipsos Healthcare partners with pharmaceutical, bio-tech and medical device manufacturers to inspire better healthcare. Operating in over 40 countries, our 700+ experts support key business decisions for our clients throughout the commercial lifecycle, from early-stage strategy, to launch, to performance optimisation. We do this through a uniquely integrated combination of therapeutic and market expertise, gold standard real world evidence, and market-leading custom research approaches – all underpinned by a global footprint and unprecedented access to today’s healthcare stakeholders.